sarepta therapeutics  wikipedia sarepta therapeutics from wikipedia the free encyclopedia jump to navigation search this article needs to be updated please update this article to reflect recent events or newly available information december  sarepta therapeutics inc nasdaq srpt is a medical research and drug development company with corporate offices and research facilities in cambridge massachusetts united states incorporated in  the company maintains some laboratory capability in corvallis oregon as of update the company does not commercialize any approved drug as of  sarepta has  issued medical patents and over  patents pending the company changed its name from avi biopharma and stock symbol from avii in july  to sarepta therapeutics and srpt respectively contents  history  products  see also  references  external links historyedit at its founding in  the company was named antivirals inc after occupying several research laboratory spaces in corvallis the company opened a production laboratory in corvallis oregon in february  and was renamed avi biopharma inc the company made headlines in  when it announced work on treatments for severe acute respiratory syndrome sars and the west nile virus in july  the company announced they would move their headquarters from portland oregon north to bothell washington near seattle at that time the company led by president and ceo leslie hudson had  employees and quarterly revenues of  million avi had yet to turn a profit nor developed any commercial products as of july  the company lost  million in the second quarter of  and then won a  million contract with the us department of defenses defense threat reduction agency in october  by this time the company had completed its headquarters move to bothell in  the company moved a second time to cambridge massachusetts at the time ceo chris garabedian indicated the move was motivated by the need to recruit expertise in rare diseases the corvallis laboratory facility was closed in  productsedit its primary products are morpholino oligomers pmos synthetic nucleic acid analogs that were conceived of by james summerton and invented by summerton with dwight weller and are being developed under the name neugene antisense since morpholino oligomers can form sequencespecific doublestranded complexes with rna they are suitable use in antisense therapy in this application a morpholino oligomer binds to messenger rna produced by a known diseasecausing gene to prevent it from being translated into protein morpholinos have been tested for a wide range of applications including prevention of cardiac restenosis after angioplasty treatment of coronary artery bypass grafts treatment of polycystic kidney disease redirection of drug metabolism duchenne muscular dystrophy dmd and infectious diseases their greatest success thus far has been in dmd and as antiviral agents the morpholino drug eteplirsen targeting exon  of the dystrophin mrna has been approved as a human therapeutic by the fda in  and clinical trials for morpholinos targeting other exons are ongoing morpholinos have been used in preclinical studies to inhibit replication of a broad range of viruses including influenza west nile virus sars hepatitis c dengue fever ebola and calicivirus all of which are single stranded rna viruses they are in advanced development for prevention and treatment of ebola and marburg viruses in march  the company announced positive results from a nonhuman primate study of avi the drug candidate for treatment of marburg virus infection the results showed that intramuscular administration of avi resulted in survival rates up to  percent in monkeys exposed to this fatal virus these results are similar to those in previous studies when the drug was given by intravenous injection in addition to development of morpholinos as therapeutics avi has conducted six human trials for colorectal and pancreatic cancers using their cancer vaccine avicine see alsoedit companies portal eteplirsen referencesedit  heres why a small biotech like sarepta has attracted so much attention boston business journal   sarepta therapeutics official website  avi biopharma changes name splits stock portland business journal july   retrieved  july    summerton j  morpholino antisense oligos applications in biopharmaceutical research innovations in pharmaceutical technology no sept retrieved  oct    archiveurl  httpwwwgenetoolscomsitesdefaultfilessummertoniptpdf  a b moody robin j november   avi biopharmas losses shrinking portland business journal retrieved    moody robin j june   avi biopharma stock reaches new week high portland business journal retrieved    a b c d dimesio robbie july   avi biopharma moving hq out of oregon the oregonian retrieved    avi biopharma loses m in q portland business journal august   retrieved    a b avi biopharma gets m military contract portland business journal october   retrieved    timmerman luke sarepta moves from seattle to boston for the talent  september   httpwwwfdagovnewseventsnewsroompressannouncementsucmhtm  sareptas marburg drug shows high survival rates after intramuscular delivery in nonhuman primates marketwire  march  external linksedit avi biopharma drops two directors shareholder group to dissolve  portland business journal v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies retrieved from httpsenwikipediaorgwindexphptitlesareptatherapeuticsoldid categories companies based in cambridge massachusettspharmaceutical companies of the united statescompanies established in companies listed on nasdaq establishments in oregonorphan drug companieslife sciences industryhealth care companies based in massachusettshidden categories wikipedia articles in need of updating from december all wikipedia articles in need of updatingarticles containing potentially dated statements from all articles containing potentially dated statements navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  june  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view sarepta therapeutics inc srpto company profile  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states profile sarepta therapeutics inc srpto related topics stocksstock screenerhealthcarebiotechnology  medical research overview news key developments people charts financials analysts research pulse srpto on nasdaq usd am edt change  chg   prev close  open  days high  days low  volume  avg vol  wk high  wk low  full description sarepta therapeutics inc incorporated on june   is a biopharmaceutical company the company focuses on the discovery and development of ribose nucleic acid rnatargeted therapeutics for the treatment of rare neuromuscular diseases the company operates through discovering developing manufacturing and delivering therapies to patients with duchenne muscular dystrophy dmd the company is primarily focused on the development of its diseasemodifying dmd drug candidatesthe company has received accelerated approval for its product exondys  indicated for the treatment of dmd in patients who have a confirmed mutation of the dmd gene that is amenable to exon  skipping exondys  is studied in clinical trials under the name of eteplirsen the company is in the process of planning several studies for eteplirsen and product candidates targeting skipping of exon  andor exon  it is also conducting an open label extension of the phase iib study for which patients can transition to commercial drug after certain criteria are met study us an open label study on ambulatory patients with a concurrent untreated control arm study promovi a study evaluating the safety and tolerability of eteplirsen in participants with advanced stage dmd study  and a study evaluating the safety and tolerability of eteplirsen in participants with early stage dmd study  each of which will allow for patients to transition to commercial drug after meeting certain criteria the company is also planning two additional phase i studiesthe company is enrolling and dosing patients in essence study  its phase iii placebo controlled confirmatory trial in patients who have a confirmed mutation of the dmd gene that is amenable to exon  or  skipping using srp and srp respectively srp an exon skipping product candidate that it has selected for development through the skipnmd consortium is in the clinic in european union eu as part of a phase iii study part i has been completed and part ii an open label portion of this study is ongoing study  it is also enrolling and dosing patients amenable to exon  skipping in essence its placebo controlled study for eteplirsen srp an exon skipping product candidate that it selected for development in collaboration with childrens national medical center cnmc in washington dc and the carolinas medical center cmc in charlotte nc in addition to exondys  the companys dmd pipeline includes other product candidates which are at various stages of developmentthe companys next generation phosphorodiamidate morpholino oligomer pmobased compounds are synthetic compounds that bind to complementary sequences of rna by standard watsoncrick nucleobase pairing when targeted to messenger rna mrna pmobased compounds downregulate protein translation by steric blockade its pmobased chemistries include peptide conjugated pmo ppmo pmox and pmoplus ppmo technology features covalent attachment of a cellpenetrating peptide to a pmo with the goal of cellular delivery into the cytosol and the nucleus pmoplus features the selective introduction of positive charges to the pmo backbone and it has potentially therapeutic applications especially for antiviral therapeutics pmox incorporates chemical modifications to the pmo backbone linkages » full overview of srpto company address sarepta therapeutics inc  st st ste cambridge   ma    p f  company web links home page officers  directors name compensation douglas ingram  sandesh mahatme  david howton  alexander cumbo  shamim ruff  » more officers  directors sarepta therapeutics inc news briefsarepta therapeutics announces pricing of  mln public offering of common stock jul   briefsarepta therapeutics announces proposed  mln public offering of common stock jul   sarepta surges after stellar dmd drug powers on jul   update sarepta surges after stellar dmd drug powers on jul   sarepta surges after robust dmd drug sales jul   » more srpto news related topics stocksstock screenerhealthcarebiotechnology  medical research sarepta therapeutics  wikipedia sarepta therapeutics from wikipedia the free encyclopedia jump to navigation search this article needs to be updated please update this article to reflect recent events or newly available information december  sarepta therapeutics inc nasdaq srpt is a medical research and drug development company with corporate offices and research facilities in cambridge massachusetts united states incorporated in  the company maintains some laboratory capability in corvallis oregon as of update the company does not commercialize any approved drug as of  sarepta has  issued medical patents and over  patents pending the company changed its name from avi biopharma and stock symbol from avii in july  to sarepta therapeutics and srpt respectively contents  history  products  see also  references  external links historyedit at its founding in  the company was named antivirals inc after occupying several research laboratory spaces in corvallis the company opened a production laboratory in corvallis oregon in february  and was renamed avi biopharma inc the company made headlines in  when it announced work on treatments for severe acute respiratory syndrome sars and the west nile virus in july  the company announced they would move their headquarters from portland oregon north to bothell washington near seattle at that time the company led by president and ceo leslie hudson had  employees and quarterly revenues of  million avi had yet to turn a profit nor developed any commercial products as of july  the company lost  million in the second quarter of  and then won a  million contract with the us department of defenses defense threat reduction agency in october  by this time the company had completed its headquarters move to bothell in  the company moved a second time to cambridge massachusetts at the time ceo chris garabedian indicated the move was motivated by the need to recruit expertise in rare diseases the corvallis laboratory facility was closed in  productsedit its primary products are morpholino oligomers pmos synthetic nucleic acid analogs that were conceived of by james summerton and invented by summerton with dwight weller and are being developed under the name neugene antisense since morpholino oligomers can form sequencespecific doublestranded complexes with rna they are suitable use in antisense therapy in this application a morpholino oligomer binds to messenger rna produced by a known diseasecausing gene to prevent it from being translated into protein morpholinos have been tested for a wide range of applications including prevention of cardiac restenosis after angioplasty treatment of coronary artery bypass grafts treatment of polycystic kidney disease redirection of drug metabolism duchenne muscular dystrophy dmd and infectious diseases their greatest success thus far has been in dmd and as antiviral agents the morpholino drug eteplirsen targeting exon  of the dystrophin mrna has been approved as a human therapeutic by the fda in  and clinical trials for morpholinos targeting other exons are ongoing morpholinos have been used in preclinical studies to inhibit replication of a broad range of viruses including influenza west nile virus sars hepatitis c dengue fever ebola and calicivirus all of which are single stranded rna viruses they are in advanced development for prevention and treatment of ebola and marburg viruses in march  the company announced positive results from a nonhuman primate study of avi the drug candidate for treatment of marburg virus infection the results showed that intramuscular administration of avi resulted in survival rates up to  percent in monkeys exposed to this fatal virus these results are similar to those in previous studies when the drug was given by intravenous injection in addition to development of morpholinos as therapeutics avi has conducted six human trials for colorectal and pancreatic cancers using their cancer vaccine avicine see alsoedit companies portal eteplirsen referencesedit  heres why a small biotech like sarepta has attracted so much attention boston business journal   sarepta therapeutics official website  avi biopharma changes name splits stock portland business journal july   retrieved  july    summerton j  morpholino antisense oligos applications in biopharmaceutical research innovations in pharmaceutical technology no sept retrieved  oct    archiveurl  httpwwwgenetoolscomsitesdefaultfilessummertoniptpdf  a b moody robin j november   avi biopharmas losses shrinking portland business journal retrieved    moody robin j june   avi biopharma stock reaches new week high portland business journal retrieved    a b c d dimesio robbie july   avi biopharma moving hq out of oregon the oregonian retrieved    avi biopharma loses m in q portland business journal august   retrieved    a b avi biopharma gets m military contract portland business journal october   retrieved    timmerman luke sarepta moves from seattle to boston for the talent  september   httpwwwfdagovnewseventsnewsroompressannouncementsucmhtm  sareptas marburg drug shows high survival rates after intramuscular delivery in nonhuman primates marketwire  march  external linksedit avi biopharma drops two directors shareholder group to dissolve  portland business journal v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies retrieved from httpsenwikipediaorgwindexphptitlesareptatherapeuticsoldid categories companies based in cambridge massachusettspharmaceutical companies of the united statescompanies established in companies listed on nasdaq establishments in oregonorphan drug companieslife sciences industryhealth care companies based in massachusettshidden categories wikipedia articles in need of updating from december all wikipedia articles in need of updatingarticles containing potentially dated statements from all articles containing potentially dated statements navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  june  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view sarepta therapeutics  wikipedia sarepta therapeutics from wikipedia the free encyclopedia jump to navigation search this article needs to be updated please update this article to reflect recent events or newly available information december  sarepta therapeutics inc nasdaq srpt is a medical research and drug development company with corporate offices and research facilities in cambridge massachusetts united states incorporated in  the company maintains some laboratory capability in corvallis oregon as of update the company does not commercialize any approved drug as of  sarepta has  issued medical patents and over  patents pending the company changed its name from avi biopharma and stock symbol from avii in july  to sarepta therapeutics and srpt respectively contents  history  products  see also  references  external links historyedit at its founding in  the company was named antivirals inc after occupying several research laboratory spaces in corvallis the company opened a production laboratory in corvallis oregon in february  and was renamed avi biopharma inc the company made headlines in  when it announced work on treatments for severe acute respiratory syndrome sars and the west nile virus in july  the company announced they would move their headquarters from portland oregon north to bothell washington near seattle at that time the company led by president and ceo leslie hudson had  employees and quarterly revenues of  million avi had yet to turn a profit nor developed any commercial products as of july  the company lost  million in the second quarter of  and then won a  million contract with the us department of defenses defense threat reduction agency in october  by this time the company had completed its headquarters move to bothell in  the company moved a second time to cambridge massachusetts at the time ceo chris garabedian indicated the move was motivated by the need to recruit expertise in rare diseases the corvallis laboratory facility was closed in  productsedit its primary products are morpholino oligomers pmos synthetic nucleic acid analogs that were conceived of by james summerton and invented by summerton with dwight weller and are being developed under the name neugene antisense since morpholino oligomers can form sequencespecific doublestranded complexes with rna they are suitable use in antisense therapy in this application a morpholino oligomer binds to messenger rna produced by a known diseasecausing gene to prevent it from being translated into protein morpholinos have been tested for a wide range of applications including prevention of cardiac restenosis after angioplasty treatment of coronary artery bypass grafts treatment of polycystic kidney disease redirection of drug metabolism duchenne muscular dystrophy dmd and infectious diseases their greatest success thus far has been in dmd and as antiviral agents the morpholino drug eteplirsen targeting exon  of the dystrophin mrna has been approved as a human therapeutic by the fda in  and clinical trials for morpholinos targeting other exons are ongoing morpholinos have been used in preclinical studies to inhibit replication of a broad range of viruses including influenza west nile virus sars hepatitis c dengue fever ebola and calicivirus all of which are single stranded rna viruses they are in advanced development for prevention and treatment of ebola and marburg viruses in march  the company announced positive results from a nonhuman primate study of avi the drug candidate for treatment of marburg virus infection the results showed that intramuscular administration of avi resulted in survival rates up to  percent in monkeys exposed to this fatal virus these results are similar to those in previous studies when the drug was given by intravenous injection in addition to development of morpholinos as therapeutics avi has conducted six human trials for colorectal and pancreatic cancers using their cancer vaccine avicine see alsoedit companies portal eteplirsen referencesedit  heres why a small biotech like sarepta has attracted so much attention boston business journal   sarepta therapeutics official website  avi biopharma changes name splits stock portland business journal july   retrieved  july    summerton j  morpholino antisense oligos applications in biopharmaceutical research innovations in pharmaceutical technology no sept retrieved  oct    archiveurl  httpwwwgenetoolscomsitesdefaultfilessummertoniptpdf  a b moody robin j november   avi biopharmas losses shrinking portland business journal retrieved    moody robin j june   avi biopharma stock reaches new week high portland business journal retrieved    a b c d dimesio robbie july   avi biopharma moving hq out of oregon the oregonian retrieved    avi biopharma loses m in q portland business journal august   retrieved    a b avi biopharma gets m military contract portland business journal october   retrieved    timmerman luke sarepta moves from seattle to boston for the talent  september   httpwwwfdagovnewseventsnewsroompressannouncementsucmhtm  sareptas marburg drug shows high survival rates after intramuscular delivery in nonhuman primates marketwire  march  external linksedit avi biopharma drops two directors shareholder group to dissolve  portland business journal v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies retrieved from httpsenwikipediaorgwindexphptitlesareptatherapeuticsoldid categories companies based in cambridge massachusettspharmaceutical companies of the united statescompanies established in companies listed on nasdaq establishments in oregonorphan drug companieslife sciences industryhealth care companies based in massachusettshidden categories wikipedia articles in need of updating from december all wikipedia articles in need of updatingarticles containing potentially dated statements from all articles containing potentially dated statements navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  june  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view global duchenne muscular dystrophy therapeutics market  fibrogen inc and pfizer sbwire marketbizstanley email alerts rss global duchenne muscular dystrophy therapeutics market  fibrogen inc and pfizer   maharashtra india  sbwire    global duchenne muscular dystrophy therapeutics market  provides a relevant source of astute data for the business planner it also examines global duchenne muscular dystrophy therapeutics market growth analysis the past and future cost demand and supply information and revenue the duchenne muscular dystrophy therapeutics industry report provides historical data of  along with a duchenne muscular dystrophy therapeutics market forecast from  to  based on duchenne muscular dystrophy therapeutics industry volume and duchenne muscular dystrophy therapeutics revenue usd million the various growth driving factors is the increase in consumer volume which is proportional to the growth of sales revenue improved situations of duchenne muscular dystrophy therapeutics market and a new approach towards duchenne muscular dystrophy therapeutics industry report synopsis duchenne muscular dystrophy dmd is a fatal genetic disorders diagnosed in children around the world dmd is often referred to as orphan or rare diseases as it affects only a small portion of the population approximately  in every  live male births however various treatment approaches are available nowadays that can inhibit progression of the disease amongst the most attractive are molecular based therapies such as mutation suppression or exon skipping the duchenne muscular dystrophy therapeutics market has very few marketed products such as emflaza translarna and exondys  the market is majorly in the research phase from which most of its revenue is generated do inquiry before purchasing report at httpsmarketbizreportglobalduchennemusculardystrophytherapeuticsmarketrninquiry the duchenne muscular dystrophy therapeutics report analyses various growth opportunities which can take this industry to the new level along with the risk factors that can prevent its growth according to the consumers the report divided into company profile contact information their contribution in market share consumer volume etc duchenne muscular dystrophy therapeutics market regionwise outlook  asiapacific duchenne muscular dystrophy therapeutics market  china  japan  korea  india  america duchenne muscular dystrophy therapeutics market  usa  canada  mexico  europe duchenne muscular dystrophy therapeutics market  germany  uk  russia key players in this report are  marathon pharmaceuticals llc  ptc therapeutics inc  sarepta therapeutics inc  italfarmaco spa  santhera pharmaceuticals  bristolmyers squibb  reveragen biopharma inc  catabasis pharmaceuticals inc  fibrogen inc  ns pharma inc  pfizer  summit therapeutics plc the duchenne muscular dystrophy therapeutics report does a comprehensive study of the market based on the extensive and rational analysis the top mergers and acquisitions of the duchenne muscular dystrophy therapeutics market are also listed in the separate sectionthe strength and weakness of the key players are also mentioned in the report get sample copy of report from here httpsmarketbizreportglobalduchennemusculardystrophytherapeuticsmarketrnrequestforsample at last the key constraints having an impact on market growth and reducing the popularity of specific product segments during the forecast period are also listed in this report the potential growth opportunities and their influence on the global duchenne muscular dystrophy therapeutics market are analyzed in the report what information does this report contain  what was the historic duchenne muscular dystrophy therapeutics market data from  to   what is the duchenne muscular dystrophy therapeutics industry growth forecast from  to   which companies direct the duchenne muscular dystrophy therapeutics market how are they positioned in the market in terms of sustainability competency production capacity and strategic outlook  what is the practical application  innovation tendency how will they derive by   which are the leading market products applications  regions and how will they perform by   a detailed survey of regulatory tendency drivers industry difficulty challenges and growth opportunities for participants about marketbiz marketbiz is designed to provide the best and most penetrating research required to all commercial industrial and profitmaking ventures in any sector of online business we take pride in our ability to satisfy the market research needs of both domestic and international businesses marketbiz has access to the worlds most comprehensive and uptodate databases in your business sector including countless market reports that can provide you with valuable data relating to your business we understand the needs of our clients and keep our reports updated as market requirement changes contact us james johnson s no  first floor office no  vishwa arcade near navale lawns pune tel  email inquirymarketbiz website httpsmarketbiz media relations contact stefen marwa research analystmarketbiz email  web  profile follow marketbizstanley   marketbizstanley  logo   related links global duchenne muscular dystrophy therapeutics market source marketbizstanley posted wednesday july   at  pm cdt  permalink   patient support and assistance  sarepta therapeutics skip to main content sarepta therapeutics sareptassist support by your side™ caring for a child with duchenne can be complicated our experienced and dedicated case managers are here to help you navigate the complexities of starting and staying on therapy our goal is to answer questions and provide information on insurance options outofpocket costs the prior authorization process onsite or athome therapy options financial assistance options other sarepta resources and programs       financial assistance programs sareptassist offers information on a range of programs including patient copay assistance program financial assistance options available to eligible patients for certain drugrelated outofpocket costs including copays coinsurance and deductibles patient assistance program pap help investigate options for patients who are uninsured and meet certain eligibility requirements patient assistance foundation support connects you with independent charitable organizations that may offer financial assistance with copays infusion costs and premiums       your personalized support starts here through sareptassist you will be connected to a dedicated case manager with experience in rare diseases including knowledge of insurance plans and healthcare networks your case manager will work with you to provide oneonone personalized support the faces of care       support throughout your treatment journey your personal sareptassist case manager is here to help get started we’re available monday through friday am – pm et sarepta  spanishspeaking case managers and interpreters for other languages are available for healthcare providers support by your patients’ side™ our team is here to help your patients navigate the process of starting and staying on therapy get your patients started in three steps         sarepta therapeutics inc nasdaqsrpt files an k entry into a material definitive agreement  market exclusive sign in join home about us privacy policy disclaimer advertise on market exclusive about marketexclusivecom contributors sitemap submit a scoop contact us become a contributor stock market news stocks analyst ratings insider trading sec filings earnings biotech stocks small caps sign in welcomelog into your accountyour usernameyour password forgot your password sign up welcomeregister for an account your emailyour username a password will be emailed to you password recovery recover your passwordyour email search sign in  joinmy account orders sign inwelcome log into your accountyour usernameyour password forgot your password get helpcreate an account create an accountwelcome register for an accountyour emailyour username a password will be emailed to you password recoveryrecover your passwordyour email a password will be emailed to you market exclusive home about us privacy policy disclaimer advertise on market exclusive about marketexclusivecom contributors sitemap submit a scoop contact us become a contributor stock market news stocks analyst ratings insider trading sec filings earnings biotech stocks small caps home sec filings sarepta therapeutics inc nasdaqsrpt files an k entry into a material definitive sec filings sarepta therapeutics inc nasdaqsrpt files an k entry into a material definitive agreement byme staff k july    share on facebook tweet on twitter sarepta therapeutics inc nasdaqsrpt files an k entry into a material definitive agreementitem  entry into a material definitive agreement on july  sarepta therapeutics inc the “company” entered into an underwriting agreement the “underwriting agreement” with goldman sachs co llc and jp morgan securities llc as representatives of the underwriters named therein collectively the “underwriters” relating to the public offering the “offering” of  shares of the company’s common stock  par value per share the “common stock” at a price to the public of  per share the “offering price” less underwriting discounts and commissions the net proceeds to the company from the sale of the common stock after deducting the underwriting discounts and commissions and other estimated offering expenses payable by the company will be approximately  million the offering is expected to close on july  subject to the satisfaction of customary closing conditions the company has also granted the underwriters a day option to purchase up to an additional  shares of common stock offered in the public offering at the offering price the offering was made to the company’s effective shelf registration statement on form s as amended file no including the prospectus dated february  as supplemented by prospectus supplement dated july  the foregoing is only a brief description of the terms of the underwriting agreement does not purport to be a complete description of the rights and obligations of the parties thereunder and is qualified in its entirety by reference to the underwriting agreement that is filed as exhibit  to this current report on form k and incorporated by reference hereinthe opinion of ropes gray llp relating to the validity of the shares to be issued in the offering is attached as exhibit  to this current report on form k on july  the company issued a press release announcing the offering and a press release announcing the pricing of the offering copies of these press releases are attached hereto as exhibits  and  in connection with the offering approximately  of shares of common stock have been allocated to douglas s ingram president and chief executive officer of the company which he intends to purchase in connection with the closing of the offering item  financial statements and exhibits d exhibits exhibit number description  underwriting agreement dated as of july   among sarepta therapeutics inc and goldman sachs  co llc and jp morgan securities llc as representatives of the underwriters named therein  opinion of ropes  gray llp  consent of ropes  gray llp included in exhibit   press release dated july    press release dated july   sarepta therapeutics inc exhibitex  ddexhtm ex ex exhibit  …to view the full exhibit click here about sarepta therapeutics inc nasdaqsrpt sarepta therapeutics inc is a biopharmaceutical company the company is focused on the discovery and development of ribonucleic acid rnatargeted therapeutics for the treatment of rare infectious and other diseases the company operates in one segment the development of pharmaceutical products on its own behalf or in collaboration with others the company through its platform technologies targets a range of diseases and disorders through rnatargeted mechanisms of action the company is also developing therapeutics using its technology for the treatment of drugresistant bacteria and infectious rare and other human diseases the company’s lead duchenne muscular dystrophy dmd product candidate eteplirsen is an antisense phosphorodiamidate morpholino oligomer pmo therapeutic in phase iii clinical development for the treatment of individuals with dmd having an error in the gene coding for dystrophin that is amenable to skipping exon  please enable javascript to view the comments powered by disqusan ad to help with our costs related articlesmore from author randolph bancorp inc nasdaqrndb files an k results of operations and financial condition national commerce corporation nasdaqncom files an k results of operations and financial condition irobot corporation nasdaqirbt files an k entry into a material definitive agreement form holdings corp nasdaqfh files an k results of operations and financial condition caesars entertainment corporation nasdaqczr files an k submission of matters to a vote of security holders caesars acquisition company nasdaqcacq files an k submission of matters to a vote of security holders subscribe to our newsletter email  first namelast nameemail a word from the sponsor latest articles pingtan marine enterprise ltd nasdaqpme files an k results of operations and financial condition rayonier advanced materials inc nyseryam files an k financial statements and exhibits armstrong world industries inc nyseawi files an k submission of matters to a vote of security holders recent posts sarepta therapeutics inc nasdaqsrpt files an k entry into a material definitive agreement randolph bancorp inc nasdaqrndb files an k results of operations and financial condition national commerce corporation nasdaqncom files an k results of operations and financial condition irobot corporation nasdaqirbt files an k entry into a material definitive agreement form holdings corp nasdaqfh files an k results of operations and financial condition sponsored editor picks here’s what just happened with neuroderm ltd nasdaqndrm july   biotech movers at both end of the space glaxosmithkline plc adr july   here’s what just happened with ironwood pharmaceuticals inc nasdaqirwd and aeterna july   popular posts this small nasdaq hidden gem may have a b drug july   weekly biotech report covering – opko health inc nyseopk intercept april   facebook inc – nasdaqfb might be moving away from its april   popular categorysec filingsanalyst ratingslsestockstech newsbiotech stocksstock market newssmall capsinsider trading about usmarket exclusive offers the latest financial news and analysis for selected us stocks and securities we are an investor driven research platform where new investment ideas from a exclusively selected group of seasoned investment analysts and qualified members from various disciplines are able to deliver their investment thesis’ across various industries and sectors our burgeoning team is comprised of individuals with strong backgrounds from various disciplines and businesses our goal is to provide an exclusive forum for contributors and users to leverage the knowledge base in order to make smarter investing decisions at market exclusive we believe that quality information from experienced well seasoned contributors provide our members with an edge that allows them to make wise investment choices market exclusive is not a registered investment brokerdealer the content on this site is for informational purposes only additionally the content on this site does not represent the views of market exclusive and is solely a representation of the authors who publish them before investing in any security you should do your own due diligence and consult with a registered broker or financial advisorcontact us email protectedfollow us sec filings stocks stock market news tech news biotech stocks featured small caps gold other news oil become a contributor about marketexclusivecom contributors advertise on market exclusive contact us  market exclusive  corporate overview  sarepta therapeutics skip to main content sarepta therapeutics our company our vision is to transform how the world approaches the treatment of serious and lifethreatening diseases by unlocking the potential of rnabased technologies recognizing the complexity of this goal we focus on rare infectious and other diseases with tremendous unmet needs—areas in which new therapies have the potential to make dramatic improvements in the lives of patients         senior leadership board of directors commitment         bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one insider trading activity sarepta therapeutics inc nasdaqsrpt – ceo bought  shares of stock  traders log in email password remember forgot password  become a member for free sign up sign up new membersign up for free new customerdiscover our portfolios united states united kingdom france deutschland schweiz de suisse fr settings dynamic quotes  offon markets equities north americaeuropeasiaoceaniamiddle east» more equities indexes dow jonessp nasdaq tsx compftse » more indexes currency  forex eur  usdgbp  usdusd  jpyusd  cadaud  usd» more currencies commodities goldcrude oil wticrude oil brentsilverplatinum» more commodities news latest news companiesmarketseconomycurrency  forexcommoditiesinterest ratesbusiness leadersfinancial calendareconomic calendar listed company analyst recorumorsiposcapital markets transactionsnew contractsprofits warningsappointmentspress releaseseventscorporate actions sector news energybasic materialsindustrialsconsumer cyclicalconsumer noncyclicalfinancialshealthcaretechnologytelecommunications servicesutilities analysis all analysiscommentariesindex analysisstock trading strategiescommodity analysisforex analysis stock picks all stock picks portfolios my portfolio virtual portfolios traders portfolios european portfoliousa portfolioasian portfolio screeners market screener homefundamental analyse top investor ratingtop trading ratingtop consensusgrowth stocksyield stockslow valuations technical analysis oversold stocksoverbought stocksclose to resistancesclose to supportsaccumulation phasemost volatile stocks watchlists my watchlists watchlists top lists yield stocksgrowth stocksundervalued stocks top  flop top news most read newshot news top fundamentals top capitalizationtop yieldtop pertop consensustop fundamentals top technicals top rsiunusual volumestop gapstop stim top movers top usatop canadatop uktop germanytop europetop asia tools market screenerdynamic chartfinancial calendareconomic calendarsector researchcurrency converter our services premium accessdiscover our services traders homepage    equities    nasdaq    sarepta therapeutics inc    srpt sarepta therapeutics inc srpt add to my list    mes dernières consultmost popular manage my lists  delayed     pm  usd    p insider trading  srpt – ceo bought  shares of stock p sarepta therape  announces its partner genethon published new mic  sarepta therapeutics announces its partner genethon published n summaryquoteschartsnewsanalysiscalendarcompanyfinancialsconsensusrevisions news summarymost relevantall newssector newstweets insider trading activity sarepta therapeutics inc nasdaqsrpt – ceo bought  shares of stock    pm cest send by mail  last name  name  from  to  you can enter multiple email addresses separated by commas message  required fields insider trading activity for sarepta therapeutics inc nasdaqsrpt douglas s ingram  ceo of sarepta therapeutics inc nasdaqsrpt reportedly bought  shares of the company’s stock at an average price of  for a total transaction amount of  sec form insider trading history for sarepta therapeutics inc nasdaqsrpt on  m kathleen behrens director bought  with an average share price of  per share and the total transaction amounting to view sec filing on  anthony r chase director bought  with an average share price of  per share and the total transaction amounting to view sec filing on sandesh mahatme cfo bought  with an average share price of  per share and the total transaction amounting to view sec filing on anthony chase director bought  with an average share price of  per share and the total transaction amounting to view sec filing on john hodgman director sold  with an average share price of  per share and the total transaction amounting to view sec filing on  m kathleen behrens director bought  with an average share price of  per share and the total transaction amounting to view sec filing on anthony chase director bought  with an average share price of  per share and the total transaction amounting to view sec filing analyst ratings for sarepta therapeutics inc nasdaqsrptthese are  hold ratings  buy ratings  strong buy rating the current consensus rating for sarepta therapeutics inc nasdaqsrpt is buy score  with a consensus target price of   a potential  upside analyst ratings history for sarepta therapeutics inc nasdaqsrpt on  susquehanna bancshares inc boost price target of rating neutral with a price target of  to on bank of america corporation initiated coverage of rating buy with a price target of on  roth capital reiterated rating buy with a price target of on  ladenburg thalmann financial services downgraded rating market perform to underperform with a price target of  to on  wbb securities reiterated rating strongbuy with a price target of  to on  wedbush reiterated rating outperform with a price target of on  goldman sachs group inc the initiated coverage of rating neutral with a price target of recent trading activity for sarepta therapeutics inc nasdaqsrptshares of sarepta therapeutics inc closed the previous trading session at  up   with  shares trading hands the post insider trading activity sarepta therapeutics inc nasdaqsrpt – ceo bought  shares of stock appeared first on market exclusive market exclusive  source market exclusive  latest news on sarepta therapeutics inc p insider trading activity sarepta the  srpt – ceo bought  shares of p sarepta therapeutics  announces its partner genethon published new microdyst  clinigen  and sarepta therapeutics launch a managed access program to treat pat  sarepta therapeutics announces its partner genethon published new microdys  sarepta therapeutics  announces pricing of  million public offering of comm  sarepta therapeutics inc nasdaq  srpt files an k entry into a material de  sarepta therapeutics inc  entry into a material definitive agreement other e  sarepta therapeutics  srpt crushes expectations  sarepta therapeutics announces pricing of  million public offering of com  sarepta therapeutics announces proposed  million public offering of commo more news news from seekingalpha a sarepta ceo ingram bullish on companys prospects buys m of stock  sarepta prices stock offering at  shares off  premarket  best and worst performing stocks on earnings  daily insider ratings round up   sanw le olbk  sarepta readies m stock offering shares slip  premarket financials  sales   m ebit   m net income   m finance   m yield   pe ratio   pe ratio  ev  sales  x ev  sales  x capitalization   m more financials chart sarepta therapeutics inc duration  auto  months  months  months  months  year  years  years  years max period  day week fullscreen chart technical analysis trends sarepta therapeutics inc short termmidtermlong termtrendsbullishbullishneutral technical analysis income statement evolution please enable javascript in your browsers settings to use dynamic charts more financials consensus sell buy mean consensus outperform number of analysts  average target price   spread  average target  consensus details eps revisions please enable javascript in your browsers settings to use dynamic charts more estimates revisions managers nametitledouglas s ingram president chief executive officer  director m kathleen behrens chairman sandesh mahatme executive vp chief financial  business officer catherine stehman breen chief medical officer hans lennart rudolf wigzell independent director more about the company sector and competitors st jancapitalization m sarepta therapeutics inc  amgen  celgene corporation  gilead sciences  regeneron pharmaceuticals  vertex pharmaceuticals  more results traderscom marketsnewsanalysisstock picksportfoliosscreenerswatchliststop  floptoolsour servicesabout surperformance sascontact usadvertiselegal informationsabout usstay connected facebooktwitterpartners börse aktien kurse und nachrichtenbest tweets copyright   surperformance all rights reserved slave flashratings  principles facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings principles  flashratings mission is to provide you  the investor  with as much honest and professional research on your investments as possible  we believe its much better to get a multitude of credible opinions on an investment than to arbitrarily follow any single advisor  be it your banker a friend or a tv pundit  flashratings does not provide advice our job is to accurately and objectively report on analysts credible research and opinions the only advice flashratings will ever give you is to absorb as much fundamental research and different opinions as possible and make your own decisions  flashratings favors covering analysts with proven track records but will cover all analysts as long as their research is honest and professional sign up » flashratings  contact us facebook autocomplete demo post a rating  month price target   trending sign up log in contact flashratings your emotional state excited confused worried upset panicked angry market report sarepta therapeutics inc  product pipeline review   about us • publishers • contact us • cart login  register all industries business  finance  business  financial services  insurance  marketing consumer  food  beverages  consumer goods  food  retailing healthcare  biotechnology  healthcare  medical devices  pharmaceuticals heavy industry  construction  energy  manufacturing  materials  transportation internet  media  ebusiness  internet  media  publishing public sector  defense  education  government telecom  computing  computer technology  fixed networks  software  wireless companycountry reports  company reports  country reports  regional reports   processing sarepta therapeutics inc  product pipeline review   jun    global markets direct   pages  usd  click here to open the popup youve added the following report to your cartclose cart summary total items subtotal      report summary table of contents companies request details related global markets directs sarepta therapeutics inc  product pipeline review   provides an overview of the sarepta therapeutics incs pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of sarepta therapeutics incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescopethe report provides brief overview of sarepta therapeutics inc including business description key information and facts and its locations and subsidiariesthe report reviews current pipeline of sarepta therapeutics incs human therapeutic division and enlists all their major and minor projectsthe report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestonesspecial feature on outlicensed and partnered product portfoliothe report summarizes all the dormant and discontinued pipeline projectslatest company statementlatest news and deals relating to the sarepta therapeutics incs pipeline productsreasons to buyevaluate sarepta therapeutics incs strategic position with total access to detailed information on its product pipelineassess the growth potential of sarepta therapeutics inc in its therapy areas of focusidentify new drug targets and therapeutic classes in the sarepta therapeutics incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areasexploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gapsdevelop strategic initiatives by understanding the focus areas of sarepta therapeutics inc and exploit collaboration and partnership opportunitiesidentify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantageplan mergers and acquisitions effectively by identifying the most promising pipeline of sarepta therapeutics incdevelop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeexplore the dormant and discontinued projects of sarepta therapeutics inc and identify potential opportunities in those areasavoid intellectual property rights related issues table of contentstable of contentslist of tableslist of figuressarepta therapeutics inc snapshotsarepta therapeutics inc overviewkey informationkey factssarepta therapeutics inc  research and development overviewkey therapeutic areassarepta therapeutics inc  pipeline reviewpipeline products by stage of developmentpipeline products  monotherapysarepta therapeutics inc  pipeline products glancesarepta therapeutics inc  late stage pipeline productsphase iii productscombination treatment modalitiessarepta therapeutics inc  clinical stage pipeline productsphase i productscombination treatment modalitiessarepta therapeutics inc  early stage pipeline productsindcta filed productscombination treatment modalitiespreclinical productscombination treatment modalitiesdiscovery productscombination treatment modalitiessarepta therapeutics inc  drug profileseteplirsenproduct descriptionmechanism of actionrd progresssrpproduct descriptionmechanism of actionrd progressaviproduct descriptionmechanism of actionrd progressradavirsenproduct descriptionmechanism of actionrd progresssrpproduct descriptionmechanism of actionrd progressantisense oligonucleotide to inhibit acpp for burkholderia cepacia infectionsproduct descriptionmechanism of actionrd progressantisense oligonucleotide to inhibit myostatin for dmd and becker mdproduct descriptionmechanism of actionrd progresspmoproduct descriptionmechanism of actionrd progresssrpproduct descriptionmechanism of actionrd progresssrpproduct descriptionmechanism of actionrd progresssrpproduct descriptionmechanism of actionrd progressantisense oligonucleotide for acinetobacter baumannii infectionsproduct descriptionmechanism of actionrd progressantisense oligonucleotide for drug resistant neisseria gonorrhoeae infectionsproduct descriptionmechanism of actionrd progressantisense oligonucleotide for drug resistant pseudomonas aeruginosa infectionsproduct descriptionmechanism of actionrd progressantisense oligonucleotide for methicillin resistant staphylococcus aureus infectionsproduct descriptionmechanism of actionrd progressantisense oligonucleotide for rare diseaseproduct descriptionmechanism of actionrd progressantisense oligonucleotide to activate lamin a for progeriaproduct descriptionmechanism of actionrd progressantisense oligonucleotide to activate lysosomal alphaglucosidase for pompe diseaseproduct descriptionmechanism of actionrd progressantisense oligonucleotide to inhibit ndm for klebsiella pneumoniae infectionsproduct descriptionmechanism of actionrd progressantisense oligonucleotide to inhibit tlrs for systemic lupus erythematosus and graft versus host diseaseproduct descriptionmechanism of actionrd progressantisense oligonucleotides for infectious diseasesproduct descriptionmechanism of actionrd progressbacterial ppmoproduct descriptionmechanism of actionrd progresssrpproduct descriptionmechanism of actionrd progresssrpproduct descriptionmechanism of actionrd progressviral pmoxproduct descriptionmechanism of actionrd progresssarepta therapeutics inc  pipeline analysissarepta therapeutics inc  pipeline products by targetsarepta therapeutics inc  pipeline products by route of administrationsarepta therapeutics inc  pipeline products by molecule typesarepta therapeutics inc  pipeline products by mechanism of actionsarepta therapeutics inc  recent pipeline updatessarepta therapeutics inc  dormant projectssarepta therapeutics inc  discontinued pipeline productsdiscontinued pipeline product profilesaviaviavisarepta therapeutics inc  company statementsarepta therapeutics inc  locations and subsidiarieshead officeother locations  subsidiariesappendixmethodologycoveragesecondary researchprimary researchexpert panel validationcontact usdisclaimerlist of tablessarepta therapeutics inc key informationsarepta therapeutics inc key factssarepta therapeutics inc  pipeline by indication sarepta therapeutics inc  pipeline by stage of development sarepta therapeutics inc  monotherapy products in pipeline sarepta therapeutics inc  phase iii sarepta therapeutics inc  phase i sarepta therapeutics inc  indcta filed sarepta therapeutics inc  preclinical sarepta therapeutics inc  discovery sarepta therapeutics inc  pipeline by target sarepta therapeutics inc  pipeline by route of administration sarepta therapeutics inc  pipeline by molecule type sarepta therapeutics inc  pipeline products by mechanism of action sarepta therapeutics inc  recent pipeline updates sarepta therapeutics inc  dormant developmental projectssarepta therapeutics inc  discontinued pipeline products sarepta therapeutics inc other locationssarepta therapeutics inc subsidiarieslist of figuressarepta therapeutics inc  pipeline by top  indication sarepta therapeutics inc  pipeline by stage of development sarepta therapeutics inc  monotherapy products in pipeline sarepta therapeutics inc  pipeline by top  target sarepta therapeutics inc  pipeline by top  route of administration sarepta therapeutics inc  pipeline by top  molecule type sarepta therapeutics inc  pipeline products by top  mechanism of action  companies mentioned in this reportsarepta therapeutics inc this report does not have a press release associated with it order today format pdf  usd license single user delivery by email   business day the fast market research advantage only the best all of our research is sourced from the most trusted and established global analysts and consultancies client focused from startups to multinationals we focus on providing the right research to our diverse client base shop securely our usbased customer service team and ecommerce systems adhere to the highest data security standards industryleading customer support individualized assistance from our expert staff is never more than an email or phone call away best price guarantee we are committed to providing the best research at the lowest cost we will match any published price for the same report guaranteed easy ordering once you’ve found the right report click ‘order now’ and complete the checkout process using any major credit card check or wirebank transferneed multiuser or enterprise license pricing contact us for a custom quote about the publisher global markets direct is a leading provider of global business intelligence and market analysis it publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industryspecific information publisher details privacy policy  terms of use  flashalerts copyright copy  fast market research inc flashratings  about us facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings  all research for my stocks the most comprehensive equity research coverage available online never miss a single piece of research upgrade downgrade or target price change by any analyst firm on any stock equity research by professional analysts  especially their rationales more than their forecasts  contains far more interesting and important information about the actual fundamentals of the traded companies than can be gathered from conventional news reports our mission is to unlock access to valuable research on stocks for all retail investors professionals institutions take advantage of our costeffective subscriptions to have flashratingss comprehensive realtime feed delivered into your intranet and trading floor platforms institutional subscriptions websites become a content licensing partner and display flashratingss popular news feed on your website content licensing advertisers advertise with us and have flashratings readers with attractive demographics take advantage of your products advertising sarepta therapeutics inc  product pipeline review    market reports center infomarketreportscentercom  us x login sign up facebook twitter linkedin google  mrc blog youtube sarepta therapeutics inc  product pipeline review   home  pharmaceuticals  global markets direct  sarepta therapeutics inc  product pipeline review   report details sarepta therapeutics inc  product pipeline review   sku gmdaug category pharmaceuticals publisher global markets direct pages  published jul skugmdaug categorypharmaceuticals publisherglobal markets direct pages published onjul request discount pay by wireinvoice description table of content list of figures request sample description sarepta therapeutics inc  product pipeline review   summary global markets directs sarepta therapeutics inc  product pipeline review   provides an overview of the sarepta therapeutics incs pharmaceutical research and development focus the report provides comprehensive information on the therapeutics under development by sarepta therapeutics inc complete with analysis by stage of development drug target mechanism of action moa route of administration roa and molecule type the report also covers the descriptive pharmacological action of the therapeutics its complete research and development history and the dormant and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites clinical trial registries conferences sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis the report helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage note certain sections in the report may be removed or altered based on the availability and relevance of data scope  the report provides a snapshot of the pipeline therapeutic landscape of sarepta therapeutics inc  the report provides overview of sarepta therapeutics inc including its business description key facts and locations and subsidiaries  the report features descriptive drug profiles for the pipeline products which includes product description descriptive moa rd brief licensing and collaboration details  other developmental activities  the report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages  the report assesses sarepta therapeutics incs pipeline therapeutics based on drug target mechanism of action moa route of administration roa and molecule type  the report features sarepta therapeutics incs outlicensed and partnered product portfolio and summarizes its dormant and discontinued projects reasons to buy  evaluate sarepta therapeutics incs strategic position with total access to detailed information on its product pipeline  gain strategically significant competitor information analysis and insights to formulate effective rd strategies  identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage  identify and understand important and diverse types of therapeutics under development for sarepta therapeutics inc  identify potential new clients or partners in the target demographic  plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics  devise corrective measures for pipeline projects by understanding sarepta therapeutics incs pipeline depth and focus of pipeline therapeutics  develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope newspress release precision medicine how the life science industry can improve outcomes through to achieve successful precision medicine at scale and to be able to offer it as an everyday treatment option researchers in drug rd need to better understand and manage the reams of unstructured datread more regenerative medicine market to hit  billion by  the current regenerative medicine market is worth  billion globally and will hit over  billion by  as impact of trump administrationread more  benefits of microneedlingmicroneedling hundreds of tiny pin pricks going into your skin might sound weird but it could just be the best thing that ever happened to your faceread more table of content table of contents table of contents  list of tables  list of figures  sarepta therapeutics inc snapshot  sarepta therapeutics inc overview  key information  key facts  sarepta therapeutics inc  research and development overview  key therapeutic areas  sarepta therapeutics inc  pipeline review  pipeline products by stage of development  pipeline products  monotherapy  sarepta therapeutics inc  pipeline products glance  sarepta therapeutics inc  late stage pipeline products  preregistration productscombination treatment modalities  sarepta therapeutics inc  clinical stage pipeline products  phase ii productscombination treatment modalities  phase i productscombination treatment modalities  sarepta therapeutics inc  early stage pipeline products  preclinical productscombination treatment modalities  discovery productscombination treatment modalities  sarepta therapeutics inc  drug profiles  eteplirsen  product description  mechanism of action  rd progress  srp  product description  mechanism of action  rd progress  srp  product description  mechanism of action  rd progress  avi  product description  mechanism of action  rd progress  radavirsen  product description  mechanism of action  rd progress  antisense oligonucleotide to inhibit acpp for burkholderia cepacia infections  product description  mechanism of action  rd progress  antisense oligonucleotide to inhibit myostatin for dmd and becker md  product description  mechanism of action  rd progress  pmo  product description  mechanism of action  rd progress  srp  product description  mechanism of action  rd progress  srp  product description  mechanism of action  rd progress  srp  product description  mechanism of action  rd progress  srp  product description  mechanism of action  rd progress  srp  product description  mechanism of action  rd progress  antisense oligonucleotide  to activate dystrophin for duchenne muscular dystrophy  product description  mechanism of action  rd progress  antisense oligonucleotide for acinetobacter baumannii infections  product description  mechanism of action  rd progress  antisense oligonucleotide for drug resistant neisseria gonorrhoeae infections  product description  mechanism of action  rd progress  antisense oligonucleotide for drug resistant pseudomonas aeruginosa infections  product description  mechanism of action  rd progress  antisense oligonucleotide for methicillin resistant staphylococcus aureus infections  product description  mechanism of action  rd progress  antisense oligonucleotide to activate dystrophin for duchenne muscular dystrophy  product description  mechanism of action  rd progress  antisense oligonucleotide to activate lamin a for progeria  product description  mechanism of action  rd progress  antisense oligonucleotide to activate lysosomal alphaglucosidase for pompe disease  product description  mechanism of action  rd progress  antisense oligonucleotide to inhibit dm protein kinase for myotonic dystrophy  product description  mechanism of action  rd progress  antisense oligonucleotide to inhibit ndm for klebsiella pneumoniae infections  product description  mechanism of action  rd progress  antisense oligonucleotide to inhibit tlrs for systemic lupus erythematosus and graft versus host disease  product description  mechanism of action  rd progress  antisense oligonucleotides for infectious diseases  product description  mechanism of action  rd progress  bacterial ppmo  product description  mechanism of action  rd progress  viral pmox  product description  mechanism of action  rd progress  sarepta therapeutics inc  pipeline analysis  sarepta therapeutics inc  pipeline products by target  sarepta therapeutics inc  pipeline products by route of administration  sarepta therapeutics inc  pipeline products by molecule type  sarepta therapeutics inc  pipeline products by mechanism of action  sarepta therapeutics inc  recent pipeline updates  sarepta therapeutics inc  dormant projects  sarepta therapeutics inc  discontinued pipeline products  discontinued pipeline product profiles  avi  avi  avi  sarepta therapeutics inc  company statement  sarepta therapeutics inc  locations and subsidiaries  head office  other locations  subsidiaries  appendix  methodology  coverage  secondary research  primary research  expert panel validation  contact us  disclaimer  list of figures list of tables sarepta therapeutics inc key information  sarepta therapeutics inc key facts  sarepta therapeutics inc  pipeline by indication   sarepta therapeutics inc  pipeline by stage of development   sarepta therapeutics inc  monotherapy products in pipeline   sarepta therapeutics inc  preregistration   sarepta therapeutics inc  phase ii   sarepta therapeutics inc  phase i   sarepta therapeutics inc  preclinical   sarepta therapeutics inc  discovery   sarepta therapeutics inc  pipeline by target   sarepta therapeutics inc  pipeline by route of administration   sarepta therapeutics inc  pipeline by molecule type   sarepta therapeutics inc  pipeline products by mechanism of action   sarepta therapeutics inc  recent pipeline updates   sarepta therapeutics inc  dormant developmental projects  sarepta therapeutics inc  discontinued pipeline products   sarepta therapeutics inc other locations  sarepta therapeutics inc subsidiaries  list of figures sarepta therapeutics inc  pipeline by top  indication   sarepta therapeutics inc  pipeline by stage of development   sarepta therapeutics inc  monotherapy products in pipeline   sarepta therapeutics inc  pipeline by top  target   sarepta therapeutics inc  pipeline by route of administration   sarepta therapeutics inc  pipeline by molecule type   sarepta therapeutics inc  pipeline products by top  mechanism of action   please select license type single user electronic pdf   site user electronic pdf   enterprise wide electronic pdf   add to cart buy now related reports global incoloy alloy ma  sales market report  global zinc dimethyldithiocarbamate market research report  global grate bars for refuse incinerators industry report  global and chinese zinc trifluoromethanesulphonate cas  industry  market research report global and chinese zinc fumarate cas  industry  market research report request sample mr mrs ms dr afghanistan  albania  algeria  andorra  angola  antigua and barbuda  argentina  armenia  australia  austria  azerbaijan  bahamas the  bahrain  bangladesh  barbados  belarus  belgium  belize  benin  bhutan  bolivia  bosnia and herzegovina  botswana  brazil  brunei  bulgaria  burkina faso  burundi  cambodia  cameroon  canada  cape verde  central african republic  chad  chile  china peoples republic of  colombia  comoros  congo congo  kinshasa  congo congo  brazzaville  costa rica  cote divoire ivory coast  croatia  cuba  cyprus  czech republic  denmark  djibouti  dominica  dominican republic  and  ecuador  egypt  el salvador  equatorial guinea  eritrea  estonia  ethiopia  fiji  finland  france  gabon  gambia the  georgia  germany  ghana  greece  grenada  guatemala  guinea  guineabissau  guyana  haiti  honduras  hungary  iceland  india  indonesia  iran  iraq  ireland  israel  italy  jamaica  japan  jordan  kazakhstan  kenya  kiribati  korea north  korea south  kuwait  kyrgyzstan  laos  latvia  lebanon  lesotho  liberia  libya  liechtenstein  lithuania  luxembourg  macedonia  madagascar  malawi  malaysia  maldives  mali  malta  marshall islands  mauritania  mauritius  mexico  micronesia  moldova  monaco  mongolia  montenegro  morocco  mozambique  myanmar burma  namibia  nauru  nepal  netherlands  new zealand  nicaragua  niger  nigeria  norway  oman  pakistan  palau  panama  papua new guinea  paraguay  peru  philippines  poland  portugal  qatar  romania  russia  rwanda  saint kitts and nevis  saint lucia  saint vincent and the grenadines  samoa  san marino  sao tome and principe  saudi arabia  senegal  serbia  seychelles  sierra leone  singapore  slovakia  slovenia  solomon islands  somalia  south africa  spain  sri lanka  sudan  suriname  swaziland  sweden  switzerland  syria  tajikistan  tanzania  thailand  timorleste east timor  togo  tonga  trinidad and tobago  tunisia  turkey  turkmenistan  tuvalu  uganda  ukraine  united arab emirates  united kingdom  united states  uruguay  uzbekistan  vanuatu  vatican city  venezuela  vietnam  yemen  zambia  zimbabwe  abkhazia  china republic of taiwan  nagornokarabakh  northern cyprus  pridnestrovie transnistria  somaliland  south ossetia  ashmore and cartier islands  christmas island  cocos keeling islands  coral sea islands  heard island and mcdonald islands  norfolk island  new caledonia  french polynesia  mayotte  saint barthelemy  saint martin  saint pierre and miquelon  wallis and futuna  french southern and antarctic lands  clipperton island  bouvet island  cook islands  niue  tokelau  guernsey  isle of man  jersey  anguilla  bermuda  british indian ocean territory  british sovereign base areas  british virgin islands  cayman islands  falkland islands islas malvinas  gibraltar  montserrat  pitcairn islands  saint helena  south georgia  south sandwich islands  turks and caicos islands  northern mariana islands  puerto rico  and  american samoa  baker island  guam  howland island  jarvis island  johnston atoll  kingman reef  midway islands  navassa island  palmyra atoll  us virgin islands  wake island  hong kong  macau  faroe islands  greenland  french guiana  guadeloupe  martinique  reunion  aland  aruba  netherlands antilles  svalbard  ascension  tristan da cunha  australian antarctic territory  ross dependency  peter i island  queen maud land  british antarctic territory  send request discount mr mrs ms dr afghanistan  albania  algeria  andorra  angola  antigua and barbuda  argentina  armenia  australia  austria  azerbaijan  bahamas the  bahrain  bangladesh  barbados  belarus  belgium  belize  benin  bhutan  bolivia  bosnia and herzegovina  botswana  brazil  brunei  bulgaria  burkina faso  burundi  cambodia  cameroon  canada  cape verde  central african republic  chad  chile  china peoples republic of  colombia  comoros  congo congo  kinshasa  congo congo  brazzaville  costa rica  cote divoire ivory coast  croatia  cuba  cyprus  czech republic  denmark  djibouti  dominica  dominican republic  and  ecuador  egypt  el salvador  equatorial guinea  eritrea  estonia  ethiopia  fiji  finland  france  gabon  gambia the  georgia  germany  ghana  greece  grenada  guatemala  guinea  guineabissau  guyana  haiti  honduras  hungary  iceland  india  indonesia  iran  iraq  ireland  israel  italy  jamaica  japan  jordan  kazakhstan  kenya  kiribati  korea north  korea south  kuwait  kyrgyzstan  laos  latvia  lebanon  lesotho  liberia  libya  liechtenstein  lithuania  luxembourg  macedonia  madagascar  malawi  malaysia  maldives  mali  malta  marshall islands  mauritania  mauritius  mexico  micronesia  moldova  monaco  mongolia  montenegro  morocco  mozambique  myanmar burma  namibia  nauru  nepal  netherlands  new zealand  nicaragua  niger  nigeria  norway  oman  pakistan  palau  panama  papua new guinea  paraguay  peru  philippines  poland  portugal  qatar  romania  russia  rwanda  saint kitts and nevis  saint lucia  saint vincent and the grenadines  samoa  san marino  sao tome and principe  saudi arabia  senegal  serbia  seychelles  sierra leone  singapore  slovakia  slovenia  solomon islands  somalia  south africa  spain  sri lanka  sudan  suriname  swaziland  sweden  switzerland  syria  tajikistan  tanzania  thailand  timorleste east timor  togo  tonga  trinidad and tobago  tunisia  turkey  turkmenistan  tuvalu  uganda  ukraine  united arab emirates  united kingdom  united states  uruguay  uzbekistan  vanuatu  vatican city  venezuela  vietnam  yemen  zambia  zimbabwe  abkhazia  china republic of taiwan  nagornokarabakh  northern cyprus  pridnestrovie transnistria  somaliland  south ossetia  ashmore and cartier islands  christmas island  cocos keeling islands  coral sea islands  heard island and mcdonald islands  norfolk island  new caledonia  french polynesia  mayotte  saint barthelemy  saint martin  saint pierre and miquelon  wallis and futuna  french southern and antarctic lands  clipperton island  bouvet island  cook islands  niue  tokelau  guernsey  isle of man  jersey  anguilla  bermuda  british indian ocean territory  british sovereign base areas  british virgin islands  cayman islands  falkland islands islas malvinas  gibraltar  montserrat  pitcairn islands  saint helena  south georgia  south sandwich islands  turks and caicos islands  northern mariana islands  puerto rico  and  american samoa  baker island  guam  howland island  jarvis island  johnston atoll  kingman reef  midway islands  navassa island  palmyra atoll  us virgin islands  wake island  hong kong  macau  faroe islands  greenland  french guiana  guadeloupe  martinique  reunion  aland  aruba  netherlands antilles  svalbard  ascension  tristan da cunha  australian antarctic territory  ross dependency  peter i island  queen maud land  british antarctic territory  send pay by wireinvoice mr mrs ms dr afghanistan  albania  algeria  andorra  angola  antigua and barbuda  argentina  armenia  australia  austria  azerbaijan  bahamas the  bahrain  bangladesh  barbados  belarus  belgium  belize  benin  bhutan  bolivia  bosnia and herzegovina  botswana  brazil  brunei  bulgaria  burkina faso  burundi  cambodia  cameroon  canada  cape verde  central african republic  chad  chile  china peoples republic of  colombia  comoros  congo congo  kinshasa  congo congo  brazzaville  costa rica  cote divoire ivory coast  croatia  cuba  cyprus  czech republic  denmark  djibouti  dominica  dominican republic  and  ecuador  egypt  el salvador  equatorial guinea  eritrea  estonia  ethiopia  fiji  finland  france  gabon  gambia the  georgia  germany  ghana  greece  grenada  guatemala  guinea  guineabissau  guyana  haiti  honduras  hungary  iceland  india  indonesia  iran  iraq  ireland  israel  italy  jamaica  japan  jordan  kazakhstan  kenya  kiribati  korea north  korea south  kuwait  kyrgyzstan  laos  latvia  lebanon  lesotho  liberia  libya  liechtenstein  lithuania  luxembourg  macedonia  madagascar  malawi  malaysia  maldives  mali  malta  marshall islands  mauritania  mauritius  mexico  micronesia  moldova  monaco  mongolia  montenegro  morocco  mozambique  myanmar burma  namibia  nauru  nepal  netherlands  new zealand  nicaragua  niger  nigeria  norway  oman  pakistan  palau  panama  papua new guinea  paraguay  peru  philippines  poland  portugal  qatar  romania  russia  rwanda  saint kitts and nevis  saint lucia  saint vincent and the grenadines  samoa  san marino  sao tome and principe  saudi arabia  senegal  serbia  seychelles  sierra leone  singapore  slovakia  slovenia  solomon islands  somalia  south africa  spain  sri lanka  sudan  suriname  swaziland  sweden  switzerland  syria  tajikistan  tanzania  thailand  timorleste east timor  togo  tonga  trinidad and tobago  tunisia  turkey  turkmenistan  tuvalu  uganda  ukraine  united arab emirates  united kingdom  united states  uruguay  uzbekistan  vanuatu  vatican city  venezuela  vietnam  yemen  zambia  zimbabwe  abkhazia  china republic of taiwan  nagornokarabakh  northern cyprus  pridnestrovie transnistria  somaliland  south ossetia  ashmore and cartier islands  christmas island  cocos keeling islands  coral sea islands  heard island and mcdonald islands  norfolk island  new caledonia  french polynesia  mayotte  saint barthelemy  saint martin  saint pierre and miquelon  wallis and futuna  french southern and antarctic lands  clipperton island  bouvet island  cook islands  niue  tokelau  guernsey  isle of man  jersey  anguilla  bermuda  british indian ocean territory  british sovereign base areas  british virgin islands  cayman islands  falkland islands islas malvinas  gibraltar  montserrat  pitcairn islands  saint helena  south georgia  south sandwich islands  turks and caicos islands  northern mariana islands  puerto rico  and  american samoa  baker island  guam  howland island  jarvis island  johnston atoll  kingman reef  midway islands  navassa island  palmyra atoll  us virgin islands  wake island  hong kong  macau  faroe islands  greenland  french guiana  guadeloupe  martinique  reunion  aland  aruba  netherlands antilles  svalbard  ascension  tristan da cunha  australian antarctic territory  ross dependency  peter i island  queen maud land  british antarctic territory  single user electronic pdf site user electronic pdf enterprise wide electronic pdf cd rom hard copy send request quote mr mrs ms dr afghanistan  albania  algeria  andorra  angola  antigua and barbuda  argentina  armenia  australia  austria  azerbaijan  bahamas the  bahrain  bangladesh  barbados  belarus  belgium  belize  benin  bhutan  bolivia  bosnia and herzegovina  botswana  brazil  brunei  bulgaria  burkina faso  burundi  cambodia  cameroon  canada  cape verde  central african republic  chad  chile  china peoples republic of  colombia  comoros  congo congo  kinshasa  congo congo  brazzaville  costa rica  cote divoire ivory coast  croatia  cuba  cyprus  czech republic  denmark  djibouti  dominica  dominican republic  and  ecuador  egypt  el salvador  equatorial guinea  eritrea  estonia  ethiopia  fiji  finland  france  gabon  gambia the  georgia  germany  ghana  greece  grenada  guatemala  guinea  guineabissau  guyana  haiti  honduras  hungary  iceland  india  indonesia  iran  iraq  ireland  israel  italy  jamaica  japan  jordan  kazakhstan  kenya  kiribati  korea north  korea south  kuwait  kyrgyzstan  laos  latvia  lebanon  lesotho  liberia  libya  liechtenstein  lithuania  luxembourg  macedonia  madagascar  malawi  malaysia  maldives  mali  malta  marshall islands  mauritania  mauritius  mexico  micronesia  moldova  monaco  mongolia  montenegro  morocco  mozambique  myanmar burma  namibia  nauru  nepal  netherlands  new zealand  nicaragua  niger  nigeria  norway  oman  pakistan  palau  panama  papua new guinea  paraguay  peru  philippines  poland  portugal  qatar  romania  russia  rwanda  saint kitts and nevis  saint lucia  saint vincent and the grenadines  samoa  san marino  sao tome and principe  saudi arabia  senegal  serbia  seychelles  sierra leone  singapore  slovakia  slovenia  solomon islands  somalia  south africa  spain  sri lanka  sudan  suriname  swaziland  sweden  switzerland  syria  tajikistan  tanzania  thailand  timorleste east timor  togo  tonga  trinidad and tobago  tunisia  turkey  turkmenistan  tuvalu  uganda  ukraine  united arab emirates  united kingdom  united states  uruguay  uzbekistan  vanuatu  vatican city  venezuela  vietnam  yemen  zambia  zimbabwe  abkhazia  china republic of taiwan  nagornokarabakh  northern cyprus  pridnestrovie transnistria  somaliland  south ossetia  ashmore and cartier islands  christmas island  cocos keeling islands  coral sea islands  heard island and mcdonald islands  norfolk island  new caledonia  french polynesia  mayotte  saint barthelemy  saint martin  saint pierre and miquelon  wallis and futuna  french southern and antarctic lands  clipperton island  bouvet island  cook islands  niue  tokelau  guernsey  isle of man  jersey  anguilla  bermuda  british indian ocean territory  british sovereign base areas  british virgin islands  cayman islands  falkland islands islas malvinas  gibraltar  montserrat  pitcairn islands  saint helena  south georgia  south sandwich islands  turks and caicos islands  northern mariana islands  puerto rico  and  american samoa  baker island  guam  howland island  jarvis island  johnston atoll  kingman reef  midway islands  navassa island  palmyra atoll  us virgin islands  wake island  hong kong  macau  faroe islands  greenland  french guiana  guadeloupe  martinique  reunion  aland  aruba  netherlands antilles  svalbard  ascension  tristan da cunha  australian antarctic territory  ross dependency  peter i island  queen maud land  british antarctic territory  send market reports center  copyright  all rights reserved facebook autocomplete demo post a rating  month price target   home trending sign up log in analyst ranking   name measured ratings sucess rate avg return  mizuho      credit suisse      jefferies      cantor fitzgerald      bank of america merrill lynch      jmp securities      goldman sachs      raymond james      fbr capital markets      william blair     our pipeline  sarepta therapeutics skip to main content sarepta therapeutics our pipeline in addition to our fdaapproved treatment for duchenne muscular dystrophy we are developing a variety of drug candidates based on our proprietary rnabased technology and unique phosphorodiamidate morpholino oligomer – or pmo – chemistry         program discovery preclinical phase i phase ii phase iii commercial   exon skipping exon  exon  exon  exon  other exon targets ppmo   gene therapy microdystrophin galgt   utrophin modulation ezutromid       internal external collaborations received accelerated approval in the us confirmatory studies required other exon targets in development      and        exonskipping for duchenne         microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft sarepta therapeutics inc company profile  bloomberg feedback sarepta therapeutics inc public company company profile sector health care industry biotech  pharma subindustry biotech sarepta therapeutics inc is a biopharmaceutical company focused on the discovery and development of unique rnabased therapeutics for the treatment of both rare and infectious diseases the company offers its products to the medical industry in countries around the world corporate information address  first street suite  cambridge ma  united states phone  fax  web url wwwsareptatherapeuticscom board members chairman company presidentceo company douglas ingram sarepta therapeutics inc advisor company edward kaye sarepta therapeutics inc board members company hans wigzell stockholm schl of entrepreneurship jeanpaul kress biogen inc show more from the web srpt news press releases sarepta ceo departure tests buyout hypothesis apr   sarepta wins approval for duchenne drug after long fda review sep   fierce fda debate on whether drug ok sets new standard sep   sareptas dmd drug fda rejection would be the right call apr   sarepta therapeutics announces its partner genethon published new microdystrophin gene therapy data in nature communications  day ago sarepta therapeutics announces pricing of  million public offering of common stock jul   sarepta therapeutics announces proposed  million public offering of common stock jul   sarepta therapeutics announces second quarter  financial results and recent corporate developments jul   clinigen and sarepta therapeutics launch a managed access program to treat patients with duchenne muscular dystrophy amenable to jul   sarepta therapeutics and clinigen launch a managed access program to treat patients with duchenne muscular dystrophy amenable t jul   sarepta therapeutics secures  million in debt financing jul   sarepta therapeutics and biomarin pharmaceutical inc announce execution of a global settlement and a license agreement resolvi jul   key executives douglas s ingram doug presidentceo sandesh mahatme sandy exec vpcfochief business ofcr catherine stehmanbreen senior vpchief med ofc david tyronne howton jr ty senior vpsecretarygen cnsl alexander cumbo bo senior vpglobal commercial shamim ruff senior vpregulatory affairs joan wood vphuman resources ian estepan investor relations sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data sarepta therapeutics inc  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports sarepta therapeutics inc  product pipeline review   sarepta therapeutics inc  product pipeline review   wgr  july  global  pages global markets direct description table of content sample report enquiry before buy related reports sarepta therapeutics inc  product pipeline review   summary global markets direct’s ‘sarepta therapeutics inc  product pipeline review  ’ provides an overview of the sarepta therapeutics inc’s pharmaceutical research and development focus the report provides comprehensive information on the therapeutics under development by sarepta therapeutics inc complete with analysis by stage of development drug target mechanism of action moa route of administration roa and molecule type the report also covers the descriptive pharmacological action of the therapeutics its complete research and development history and the dormant and discontinued projects global markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites clinical trial registries conferences sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis the report helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage note certain sections in the report may be removed or altered based on the availability and relevance of data scope  the report provides a snapshot of the pipeline therapeutic landscape of sarepta therapeutics inc  the report provides overview of sarepta therapeutics inc including its business description key facts and locations and subsidiaries  the report features descriptive drug profiles for the pipeline products which includes product description descriptive moa rd brief licensing and collaboration details  other developmental activities  the report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages  the report assesses sarepta therapeutics inc’s pipeline therapeutics based on drug target mechanism of action moa route of administration roa and molecule type  the report features sarepta therapeutics inc’s outlicensed and partnered product portfolio and summarizes its dormant and discontinued projects reasons to buy  evaluate sarepta therapeutics inc’s strategic position with total access to detailed information on its product pipeline  gain strategically significant competitor information analysis and insights to formulate effective rd strategies  identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage  identify and understand important and diverse types of therapeutics under development for sarepta therapeutics inc  identify potential new clients or partners in the target demographic  plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics  devise corrective measures for pipeline projects by understanding sarepta therapeutics inc’s pipeline depth and focus of pipeline therapeutics  develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope table of contents table of contents  list of tables  list of figures  sarepta therapeutics inc snapshot  sarepta therapeutics inc overview  key information  key facts  sarepta therapeutics inc  research and development overview  key therapeutic areas  sarepta therapeutics inc  pipeline review  pipeline products by stage of development  pipeline products  monotherapy  sarepta therapeutics inc  pipeline products glance  sarepta therapeutics inc  late stage pipeline products  preregistration productscombination treatment modalities  sarepta therapeutics inc  clinical stage pipeline products  phase ii productscombination treatment modalities  phase i productscombination treatment modalities  sarepta therapeutics inc  early stage pipeline products  preclinical productscombination treatment modalities  discovery productscombination treatment modalities  sarepta therapeutics inc  drug profiles  eteplirsen  product description  mechanism of action  rd progress  srp  product description  mechanism of action  rd progress  srp  product description  mechanism of action  rd progress  avi  product description  mechanism of action  rd progress  radavirsen  product description  mechanism of action  rd progress  antisense oligonucleotide to inhibit acpp for burkholderia cepacia infections  product description  mechanism of action  rd progress  antisense oligonucleotide to inhibit myostatin for dmd and becker md  product description  mechanism of action  rd progress  pmo  product description  mechanism of action  rd progress  srp  product description  mechanism of action  rd progress  srp  product description  mechanism of action  rd progress  srp  product description  mechanism of action  rd progress  srp  product description  mechanism of action  rd progress  srp  product description  mechanism of action  rd progress  antisense oligonucleotide  to activate dystrophin for duchenne muscular dystrophy  product description  mechanism of action  rd progress  antisense oligonucleotide for acinetobacter baumannii infections  product description  mechanism of action  rd progress  antisense oligonucleotide for drug resistant neisseria gonorrhoeae infections  product description  mechanism of action  rd progress  antisense oligonucleotide for drug resistant pseudomonas aeruginosa infections  product description  mechanism of action  rd progress  antisense oligonucleotide for methicillin resistant staphylococcus aureus infections  product description  mechanism of action  rd progress  antisense oligonucleotide to activate dystrophin for duchenne muscular dystrophy  product description  mechanism of action  rd progress  antisense oligonucleotide to activate lamin a for progeria  product description  mechanism of action  rd progress  antisense oligonucleotide to activate lysosomal alphaglucosidase for pompe disease  product description  mechanism of action  rd progress  antisense oligonucleotide to inhibit dm protein kinase for myotonic dystrophy  product description  mechanism of action  rd progress  antisense oligonucleotide to inhibit ndm for klebsiella pneumoniae infections  product description  mechanism of action  rd progress  antisense oligonucleotide to inhibit tlrs for systemic lupus erythematosus and graft versus host disease  product description  mechanism of action  rd progress  antisense oligonucleotides for infectious diseases  product description  mechanism of action  rd progress  bacterial ppmo  product description  mechanism of action  rd progress  viral pmox  product description  mechanism of action  rd progress  sarepta therapeutics inc  pipeline analysis  sarepta therapeutics inc  pipeline products by target  sarepta therapeutics inc  pipeline products by route of administration  sarepta therapeutics inc  pipeline products by molecule type  sarepta therapeutics inc  pipeline products by mechanism of action  sarepta therapeutics inc  recent pipeline updates  sarepta therapeutics inc  dormant projects  sarepta therapeutics inc  discontinued pipeline products  discontinued pipeline product profiles  avi  avi  avi  sarepta therapeutics inc  company statement  sarepta therapeutics inc  locations and subsidiaries  head office  other locations  subsidiaries  appendix  methodology  coverage  secondary research  primary research  expert panel validation  contact us  disclaimer  list of tables sarepta therapeutics inc key information  sarepta therapeutics inc key facts  sarepta therapeutics inc  pipeline by indication   sarepta therapeutics inc  pipeline by stage of development   sarepta therapeutics inc  monotherapy products in pipeline   sarepta therapeutics inc  preregistration   sarepta therapeutics inc  phase ii   sarepta therapeutics inc  phase i   sarepta therapeutics inc  preclinical   sarepta therapeutics inc  discovery   sarepta therapeutics inc  pipeline by target   sarepta therapeutics inc  pipeline by route of administration   sarepta therapeutics inc  pipeline by molecule type   sarepta therapeutics inc  pipeline products by mechanism of action   sarepta therapeutics inc  recent pipeline updates   sarepta therapeutics inc  dormant developmental projects  sarepta therapeutics inc  discontinued pipeline products   sarepta therapeutics inc other locations  sarepta therapeutics inc subsidiaries  list of figures sarepta therapeutics inc  pipeline by top  indication   sarepta therapeutics inc  pipeline by stage of development   sarepta therapeutics inc  monotherapy products in pipeline   sarepta therapeutics inc  pipeline by top  target   sarepta therapeutics inc  pipeline by route of administration   sarepta therapeutics inc  pipeline by molecule type   sarepta therapeutics inc  pipeline products by top  mechanism of action   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm united states blood bag tube thermosealers market report  in this report the united states blood bag tube thermosealers market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx betwee united states hemodialysis powder solution market report  in this report the united states hemodialysis powder solution market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx betwee united states hemodialyzer market report  in this report the united states hemodialyzer market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx between  and  united states intravenous infusion pump market report  in this report the united states intravenous infusion pump market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx between  global veterinary vaccine market research report  in this report the global veterinary vaccine market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx between  and   purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports united states blood bag tube thermosealers market report  published  july  united states hemodialysis powder solution market report  published  july  united states hemodialyzer market report  published  july  united states intravenous infusion pump market report  published  july  global veterinary vaccine market research report  published  july  × tell a friend about this report your name your email friends name friends email your enquiry send sarepta therapeutics and biomarin pharmaceutical inc announce execution of a global settlement and a license agreement resolving exon skipping patent litigationhomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets close in  hrs  minssp  dow  todays chartsdont get blindsided by teslas shiny new model sarepta therapeutics and biomarin pharmaceutical inc announce execution of a global settlement and a license agreement resolving exon skipping patent litigationglobenewswire•july  reblogsharetweetsharecambridge mass and san rafael calif july   globe newswire  sarepta therapeutics inc srpt a us commercialstage biopharmaceutical company focused on the discovery and development of unique rnatargeted therapeutics for the treatment of rare neuromuscular diseases and biomarin pharmaceutical inc bmrn a leading biotechnology company in therapies for rare genetic diseases announced today that sarepta and biomarin executed a license agreement that provides sarepta therapeutics with global exclusive rights to biomarin’s dmd patent estate for exondys  and all future exonskipping products biomarin retains the right to convert the license to a coexclusive right in the event it decides to proceed with an exonskipping therapy for dmd in addition sarepta and biomarin executed a settlement agreement resolving the ongoing worldwide patent proceedings related to the use of exondys  and all future exonskipping products for the treatment of dmd the effectiveness of the agreements is subject to closing conditions including execution of necessary approvals by academisch ziekenhuis leiden azl by july  under the terms of the license and settlement agreements sarepta will make a onetime payment of  million to biomarin and certain additional regulatory and commercial milestone payments for exons    and possibly on future exonskipping productsin addition sarepta will pay royalties to biomarin as followsexonskipping compounds   and  and possibly on future exonskipping products sarepta will pay biomarin  percent of net sales through the end of  in the united states andexonskipping compounds   and  and possibly on future exonskipping products sarepta will pay biomarin  percent of net sales through september   in the european union and in other countries where certain biomarin  azl patents exist“upon their effectiveness these global license and settlement agreements provide sarepta worldwide freedom to operate for exondys  and our future exonskipping products” said douglas ingram sarepta’s president and chief executive officer “the resolution of these legal matters provides us with more certainty to fully focus our resources and energy on our crucial mission of developing innovative medicines to improve the lives of those impacted by dmd around the world“we are pleased to reach a global settlement and license agreement with sarepta that fairly recognizes the important innovation by the leiden university medical center and allows patients certainty that this issue will not create a barrier to access” said g eric davis biomarin’s executive vice president and general counselabout exondys exondys  uses sarepta’s proprietary phosphorodiamidate morpholino oligomer pmo chemistry and exonskipping technology to skip exon  of the dystrophin gene exondys  is designed to bind to exon  of dystrophin premrna resulting in exclusion of this exon during mrna processing in patients with genetic mutations that are amenable to exon  skipping exon skipping is intended to allow for production of an internally truncated dystrophin protein data from clinical studies of exondys  in a small number of dmd patients have demonstrated a consistent safety and tolerability profile the pivotal trials were not designed to evaluate longterm safety and a clinical benefit of exondys  has not been establishedimportant safety informationadverse reactions in dmd patients n treated with exondys   or  mgkgweek by intravenous iv infusion with an incidence of at least  more than placebo n study   weeks were exondys  placebo balance disorder   vomiting   and contact dermatitis   the most common adverse reactions were balance disorder and vomiting because of the small numbers of patients these represent crude frequencies that may not reflect the frequencies observed in practice the  mgkg once weekly dosing regimen of exondys  is not recommendedin the  patients who received ≥ mgkgweek of exondys  for up to  weeks in clinical studies the following events were reported in ≥ of patients and occurred more frequently than on the same dose in study  vomiting contusion excoriation arthralgia rash catheter site pain and upper respiratory tract infectionthere have been reports of transient erythema facial flushing and elevated temperature occurring on the day of exondys  infusionabout sarepta therapeuticssarepta therapeutics is a us commercialstage biopharmaceutical company focused on the discovery and development of unique rnatargeted therapeutics for the treatment of rare neuromuscular diseases the company is primarily focused on rapidly advancing the development of its potentially diseasemodifying duchenne muscular dystrophy dmd drug candidates for more information please visit wwwsareptacomread moreabout biomarin pharmaceutical incbiomarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and lifethreatening rare disorders the companys portfolio consists of six commercialized products and multiple clinical and preclinical product candidates for additional information please visit wwwbiomarincom information on biomarins website is not incorporated by reference into this press releaseforwardlooking statementsthis press release contains statements that are forwardlooking any statements contained in this press release that are not statements of historical fact may be deemed to be forwardlooking statements words such as believes anticipates plans expects will intends potential possible and similar expressions are intended to identify forwardlooking statements these forwardlooking statements include statements about the license agreement providing sarepta with global exclusive rights to biomarin’s dmd patent estate for exondys  and all future exonskipping products the settlement agreement resolving the ongoing worldwide patent proceedings related to the use of exondys  and all future exonskipping products for the treatment of dmd the payments and royalties that sarepta will be making as part of the settlement and license agreements the settlement and license agreements providing for sareptas worldwide freedom to operate for exondys  and sarepta’s future exonskipping products the settlement providing sarepta with the certainty to fully focus its resources and energy on its crucial mission of developing innovative medicines to improve the lives of those impacted by dmd around the world and the statement that the patent proceedings between the parties will not create for patients a barrier to access to the innovation by the leiden university medical centerthese forwardlooking statements involve risks and uncertainties many of which are beyond sareptas control known risk factors include among others the settlement and license agreements may not become effective if their conditions to effectiveness are not met within the required deadline the parties may not be able to fulfill their commitments and obligations under the settlement and license agreements any future claims of infringement by other third parties the expected benefits and opportunities related to the settlement and license agreements between the parties may not be realized or may take longer to realize than expected due to challenges and uncertainties regarding the sales of exondys  and the research and development of future exonskipping products sarepta may experience significant fluctuations in sales of exondys  from period to period and ultimately sarepta may never generate sufficient revenues from exondys  to reach or maintain profitability or sustain its anticipated levels of operations sarepta may never receive regulatory approval to its future exonskipping products due to a variety of reasons including that the results of additional research may not be consistent with past results or may not be positive or may otherwise fail to meet regulatory approval requirements for the safety and efficacy of product candidates  and even if sarepta obtains regulatory approvals it may not achieve any significant revenues from the sale of such products sarepta may not have worldwide freedom to operate for exondys  and sarepta’s future exonskipping products due to future proceedings brought by other partiesany of the foregoing risks could adversely affect sareptas business results of operations and the trading price of sareptas common stock for a detailed description of risks and uncertainties sarepta faces you are encouraged to review sareptas  annual report on form k and most recent quarterly report on form q for the quarter ended march   filed with the securities and exchange commission sec as well as other sec filings made by sarepta we caution investors not to place considerable reliance on the forwardlooking statements contained in this press release sarepta does not undertake any obligation to publicly update its forwardlooking statements based on events or circumstances after the date hereofinternet posting of informationwe routinely post information that may be important to investors in the for investors section of our website at wwwsareptacom we encourage investors and potential investors to consult our website regularly for important information about us source sarepta therapeutics increblogsharetweetsharerecently viewedyour list is emptywhat to read nextmaryland board oks settlement in police custody death caseassociated pressthis will be in everyones household by banyan hillsponsoredcan biomarin bmrn keep the earnings streak alive in qzacksthe two pizza rule is a secret to productive meetings that helped amazon ceo jeff bezos become one of the worlds richest menbusiness insiderthe real reason overseas manufacturing is coming to americayahoo financeengineer finds pattern makes millions in stocksmoney morningsponsoredtodays charts dont get blindsided by teslas shiny new model yahoo financesbux unicorn frap wasn’t magical enough to save earningsyahoo finance videohow a oneofakind business has kept  kitchens out of landfillsyahoo financezuckerberg wifes ambitious secret finally exposedunewzmesponsoredtax cuts just got more likelyyahoo financetrump’s unwitting legacy could be universal health coverageyahoo finance ways to break free from your credit card debtyahoo financepeople in heavy debt may be in for a big surprisefreedom debt reliefsponsoredhere’s where you can go to see the historic solar eclipseyahoo finance videostocks whiff as earnings and economic data pour inyahoo financejeff sessions shouldn’t resign he should force trump to fire himtruthbetold trump has reduced the stature of all cabinet posts to a very sad statejoin the conversation   sarepta therapeutics  focused on rnatargeted therapeutics skip to main content sarepta therapeutics homepage sa sarepta therapeutics receives accelerated approval for duchenne muscular dystrophy drugread the press release to learn more       the promise of science realized™ we are sarepta therapeutics a commercialstage biopharmaceutical company focused on the discovery and development of unique rnatargeted therapeutics for the treatment of rare neuromuscular diseases our primary focus is on rapidly advancing the development of our potentially diseasemodifying duchenne muscular dystrophy dmd drug candidates our science sareptassist™ duchenne program strategic partnerships dedicated patient support our commitment to the patients and families impacted by duchenne muscular dystrophy extends beyond treatment we are proud to offer sareptassist™ a patient support program for those seeking information on therapy transformation within reach™ our unique rnabased technology has the potential to advance treatments in numerous areas of high unmet need we are continuing to advance our clinical programs for duchenne muscular dystrophy turning discovery into recovery™ we seek collaborations with leaders in industry government and academia to make meaningful advances in medicine our proprietary and highly versatile rnatargeted technologies form the foundation of our partnering strategy